Celsis on track to announce strong results

UK-based Celsis says it has made significant progress in the first half of the year and is on track to announce strong revenue and solid operating profit growth for the six months ended September 30, 2007.

The Rapid Detection division is performing very well and has made a strong recovery from last year's first-half performance following a temporary slow down in instrument sales due to industry consolidations. Focus on the pharmaceutical market continues as this division expands its presence in the rapidly growing microbial contamination market, notes Celsis. Rapid testing reagent sales remain healthy and instrument placements have improved across all segments of this business.

The Analytical Services division is also performing well at both of its Missouri and New Jersey locations in the USA, although it has seen a significant chemistry contract in the latter wind down which will moderate the improved breadth of growth during the period, the firm warns. This business remains strong overall and is benefiting from last year's exceptional revenue increases, from the New Jersey Chemistry business, and is consolidating these significant increases in growth.